Virax Biolabs Group Ltd

VRAX

Exchange: Nasdaq
Industry: In Vitro & In Vivo Diagnostic Substances
SEC CIK: 0001885827

SEC filings (opens in a new tab)

No open-market purchases or sales by Virax Biolabs Group Ltd insiders were filed in the last 90 days; 2 institutions reported holding it in 13F filings for Q2 2026, worth $77.6K in total; no superinvestor holds it.

Superinvestors holding VRAX, Q2 2026

See all superinvestors

No superinvestor reported holding VRAX in Q2 2026.